Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

Galit Weinstein; Alexa S. Beiser; Sarah R. Preis; Paul Courchesne; Vincent Chouraki; Daniel Levy; Sudha Seshadri

doi:10.1016/j.dadm.2016.06.005

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

Galit Weinstein, Alexa S. Beiser, Sarah R. Preis, Paul Courchesne, Vincent Chouraki, Daniel Levy, Sudha Seshadri

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke. Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models and examined potential interactions. Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64-23.89; P =.007) and with decreased risk of dementia (HR = 0.53, 0.32-0.88; P =.013) and stroke (HR = 0.78, 0.63-0.97; P =.029) among younger participants. Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age-related factor.

Original language	English
Pages (from-to)	103-109
Number of pages	7
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	3
DOIs	https://doi.org/10.1016/j.dadm.2016.06.005
State	Published - 2016
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and by grants from the National Institute of Neurological Disorders and Stroke ( NS017950 ), the National Heart, Lung and Blood Association ( HL93029 , U01HL 096917 ) and the National Institute on Aging ( AG008122 , AG016495 , AG033193 , AG031287 , U01AG049505 , U01AG049607 ) and by the Division of Intramural Research, National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Heart Lung and Blood Institute, the National Institute on Aging, or the National Institutes of Health.

Publisher Copyright:
© 2016 The Authors.

Keywords

Alzheimer's disease
Dementia
Epidemiology
Plasma clusterin
Risk factors
Stroke

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.dadm.2016.06.005

Cite this

@article{0a0d86758c2b4a52ab484a218960f32e,

title = "Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke",

abstract = "Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke. Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models and examined potential interactions. Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64-23.89; P =.007) and with decreased risk of dementia (HR = 0.53, 0.32-0.88; P =.013) and stroke (HR = 0.78, 0.63-0.97; P =.029) among younger participants. Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age-related factor.",

keywords = "Alzheimer's disease, Dementia, Epidemiology, Plasma clusterin, Risk factors, Stroke",

author = "Galit Weinstein and Beiser, {Alexa S.} and Preis, {Sarah R.} and Paul Courchesne and Vincent Chouraki and Daniel Levy and Sudha Seshadri",

note = "Funding Information: This work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and by grants from the National Institute of Neurological Disorders and Stroke ( NS017950 ), the National Heart, Lung and Blood Association ( HL93029 , U01HL 096917 ) and the National Institute on Aging ( AG008122 , AG016495 , AG033193 , AG031287 , U01AG049505 , U01AG049607 ) and by the Division of Intramural Research, National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Heart Lung and Blood Institute, the National Institute on Aging, or the National Institutes of Health. Publisher Copyright: {\textcopyright} 2016 The Authors.",

year = "2016",

doi = "10.1016/j.dadm.2016.06.005",

language = "English",

volume = "3",

pages = "103--109",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier",

}

TY - JOUR

T1 - Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

AU - Weinstein, Galit

AU - Beiser, Alexa S.

AU - Preis, Sarah R.

AU - Courchesne, Paul

AU - Chouraki, Vincent

AU - Levy, Daniel

AU - Seshadri, Sudha

N1 - Funding Information: This work was supported by the dedication of the Framingham Heart Study participants, the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and by grants from the National Institute of Neurological Disorders and Stroke ( NS017950 ), the National Heart, Lung and Blood Association ( HL93029 , U01HL 096917 ) and the National Institute on Aging ( AG008122 , AG016495 , AG033193 , AG031287 , U01AG049505 , U01AG049607 ) and by the Division of Intramural Research, National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Heart Lung and Blood Institute, the National Institute on Aging, or the National Institutes of Health. Publisher Copyright: © 2016 The Authors.

PY - 2016

Y1 - 2016

N2 - Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke. Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models and examined potential interactions. Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64-23.89; P =.007) and with decreased risk of dementia (HR = 0.53, 0.32-0.88; P =.013) and stroke (HR = 0.78, 0.63-0.97; P =.029) among younger participants. Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age-related factor.

AB - Introduction: Genetic variation in the clusterin gene has been associated with Alzheimer Disease (AD), and the clusterin protein is thought to play a mechanistic role. We explored the associations of clusterin plasma levels with incident dementia, AD, and stroke. Methods: Plasma clusterin was assessed in 1532 nondemented participants from the Framingham Study Offspring cohort between 1998 and 2001 (mean age, 69 ± 6; 53% women). We related clusterin levels to risk of incident dementia, AD, and stroke using Cox-proportional hazards models and examined potential interactions. Results: A significant interaction of plasma clusterin levels with age was observed. Clusterin was significantly associated with increased risk of dementia among elderly persons (>80 years; hazard ratio [HR], 95% confidence interval = 6.25, 1.64-23.89; P =.007) and with decreased risk of dementia (HR = 0.53, 0.32-0.88; P =.013) and stroke (HR = 0.78, 0.63-0.97; P =.029) among younger participants. Discussion: The association between plasma clusterin levels and risk of dementia and stroke may be modified by age or an age-related factor.

KW - Alzheimer's disease

KW - Dementia

KW - Epidemiology

KW - Plasma clusterin

KW - Risk factors

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84978536011&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.06.005

DO - 10.1016/j.dadm.2016.06.005

M3 - Article

AN - SCOPUS:84978536011

SN - 2352-8729

VL - 3

SP - 103

EP - 109

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this